User:James Bahng/sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 7: Line 7:
The mechanism is not well understood, but is hypothesized that His-133 activates a nucleophilic water, which attacks the δ carbon, leading to cleavage<ref name=”1”> Bateman, R.L., Bhanumoorthy, P., Witte, J.F., McClard, R.W., Grompe, M., Timm, D.E. (2001) Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound
The mechanism is not well understood, but is hypothesized that His-133 activates a nucleophilic water, which attacks the δ carbon, leading to cleavage<ref name=”1”> Bateman, R.L., Bhanumoorthy, P., Witte, J.F., McClard, R.W., Grompe, M., Timm, D.E. (2001) Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound
Phosphorus-based Inhibitor. Journal of Biological Chemistry, 207(18) 15284-15291
Phosphorus-based Inhibitor. Journal of Biological Chemistry, 207(18) 15284-15291
-
</ref>. The resultant tetrahedral alkoxy transition state is thought to be stabazlied by Arg-237, Gln-240, and Lys-253 residues. As with all of the EC 3.7.1 class enzymes, the key to the C-C cleavage is the metal ion that lines up with the carbon to be cleaved.
+
</ref>. The resultant tetrahedral alkoxy transition state is thought to be stabilized by Arg-237, Gln-240, and Lys-253 residues. As with all of the EC 3.7.1 class enzymes, the key to the C-C cleavage is the metal ion that lines up with the carbon to be cleaved.
== Disease and Treatment ==
== Disease and Treatment ==
-
Mutations in 1HYO are responsible for hereditary tyrosemia Type I, a serious metabolic disease resulting in chronic inflammation of the liver and neuronal damage<ref name="2"> Grompe, M. (2001)The Pathophysiology and Treatment of Hereditary Tyrosinemia Type 1. Liver Diease, 21(4):563-572 DOI:10.1055/s-2001-19035</ref>. It is in the same metabolic pathway as Phenylketonuria (PKU) in infants, and is treated similarly with strict dietary control and pharmacological inhibition of Phenylalanine hydroxylase, the key first enzyme in the degradation pathway.
+
Mutations in 1HYO are responsible for hereditary tyrosemia Type I, a serious metabolic disease resulting in chronic inflammation of the liver and neuronal damage<ref name="2"> Grompe, M. (2001)The Pathophysiology and Treatment of Hereditary Tyrosinemia Type 1. Liver Diease, 21(4):563-572 DOI:10.1055/s-2001-19035</ref>. It is in the same metabolic pathway as Phenylketonuria (PKU) in infants, and is treated similarly with strict lifelong dietary control and pharmacological inhibition of [[http://ec.asm.org/content/6/3/514/F1.large.jpg Phenylalanine hydroxylase]], the key first enzyme in the degradation pathway.
In very serious acute cases, double liver/kidney transplant may be considered as an option as well.
In very serious acute cases, double liver/kidney transplant may be considered as an option as well.

Revision as of 05:11, 1 April 2014

Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor

Fumarylacetoacetate Hydrolase

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

James Bahng

Personal tools